Amedisys, Inc. (NASDAQ:AMED) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 52.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 12,824 shares of the health services provider's stock after selling 14,189 shares during the quarter. Bridgewater Associates LP's holdings in Amedisys were worth $1,238,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Citigroup Inc. boosted its stake in shares of Amedisys by 7.2% in the third quarter. Citigroup Inc. now owns 192,768 shares of the health services provider's stock valued at $18,604,000 after buying an additional 12,911 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Amedisys by 2.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider's stock valued at $33,400,000 after acquiring an additional 9,004 shares during the period. Amara Financial LLC. purchased a new stake in shares of Amedisys during the 3rd quarter worth $526,000. KBC Group NV acquired a new position in shares of Amedisys during the 3rd quarter worth $63,000. Finally, State of New Jersey Common Pension Fund D increased its holdings in shares of Amedisys by 1.7% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 20,357 shares of the health services provider's stock valued at $1,965,000 after purchasing an additional 339 shares in the last quarter. Institutional investors and hedge funds own 94.36% of the company's stock.

Amedisys Price Performance

AMED stock traded down $0.17 during trading on Monday, reaching $91.24. 376,793 shares of the company were exchanged, compared to its average volume of 357,201. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock's 50 day moving average price is $94.74 and its 200 day moving average price is $95.62. Amedisys, Inc. has a 52-week low of $88.81 and a 52-week high of $98.95. The company has a market cap of $2.99 billion, a P/E ratio of 36.27, a PEG ratio of 1.92 and a beta of 0.78.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $587.67 million for the quarter, compared to analysts' expectations of $586.75 million. During the same period last year, the firm earned $0.98 EPS. Amedisys's revenue was up 5.7% compared to the same quarter last year. As a group, analysts predict that Amedisys, Inc. will post 4.55 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.